AIM ImmunoTech
31 hedge funds and large institutions have $2.05M invested in AIM ImmunoTech in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 5 closing their positions.
23% more capital invested
Capital invested by funds: $1.67M → $2.05M (+$377K)
11% less funds holding
Funds holding: 35 → 31 (-4)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$16.5K |
| 2 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$10.4K |
| 3 |
BlackRock
New York
|
+$1.76K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$1.14K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$881 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$159K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$49.5K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$21.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$15.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HI
26
Hoey Investments
Coatesville,
Pennsylvania
| $430 | – | – | – |
|
27
Wells Fargo
San Francisco,
California
| $315 | – | – | – |
|
|
CFGS
28
Concourse Financial Group Securities
Birmingham,
Alabama
| $215 | – | – | – |
|
|
TWC
29
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $96 | – | – | – |
|
|
CCMI
30
Creative Capital Management Investments
San Diego,
California
| $86 | – | – | – |
|
|
HNB
31
Huntington National Bank
Columbus,
Ohio
| $25 | – | – | – |
|
|
NMG
32
New Millennium Group
Sandy,
Utah
| $14 | – | – | – |
|
|
33
UBS Group
Zurich,
Switzerland
| $6 | -$15.2K | -293 | Closed |
|
|
RJFSA
34
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$11.5K | -370 | Closed |
|
|
VF
35
Virtu Financial
New York
| – | -$10K | -321 | Closed |
|
36
Millennium Management
New York
| – | -$6K | -182 | Closed |
|
37
Bank of America
Charlotte,
North Carolina
| – | -$52 | -1 | Closed |
|
|
CS
38
Credit Suisse
Zurich,
Switzerland
| – | -$3 | – | – |
|
AIM Hedge Fund Activity: Q1 2023 in Review
31 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q1 2023, worth a combined $2.05M — up 23% from $1.67M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of AIM and 1 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $16.5K. The largest seller was Morgan Stanley, cutting an estimated $159K.
- 31 institutional investors held AIM ImmunoTech (AIM) as of Q1 2023, down from 35 in Q4 2022.
- Funds reported $2.05M of AIM ImmunoTech stock for Q1 2023, up 23% quarter-over-quarter.
- 1 fund opened new AIM ImmunoTech positions in Q1 2023 and 5 closed out, a net change of -4 holders.
- The largest AIM ImmunoTech buyer in Q1 2023 was Renaissance Technologies, an estimated $16.5K added.
- The largest AIM ImmunoTech seller in Q1 2023 was Morgan Stanley, an estimated $159K sold.
Based on aggregated 13F filings for Q1 2023.